Bolt Biotherapeutics IncNASDAQ:BOLT
- LAST PRICE1.1800
- TODAY'S CHANGE (%)0.0200 (1.7241%)
- Bid / Lots1.1500/ 50
- Ask / Lots1.1900/ 1
- Open / Previous Close1.2000 / 1.1600
- Day Range
- 52 Week Range
- Volume554
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BOLT |
|---|---|---|
| 09:41 ET | 100 | 1.2 |
| 09:45 ET | 300 | 1.18 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bolt Biotherapeutics Inc | 44.2M | -0.6x | --- |
Aspira Women's Health Inc | 40.5M | -1.9x | --- |
Jaguar Health Inc | 47.0M | 0.0x | --- |
Correlate Energy Corp | 59.2M | -4.1x | --- |
Kezar Life Sciences Inc | 57.5M | -0.6x | --- |
DURECT Corp | 28.4M | -0.8x | --- |
Company Information
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Contact Information
- Headquarters
- 900 Chesapeake DriveREDWOOD CITY, CA, United States 94063
- Phone
- 650-665-9295
- Fax
- 302-531-3150
Executives
- Chief Executive Officer, Director
- Randall Schatzman
- Chief Financial Officer
- William Quinn
- Chief Medical Officer
- Edith Perez
- Chief Business Officer
- Grant Yonehiro
- Lead Independent Director
- James Healy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $44.2M |
|---|---|
Revenue (TTM) | $7.9M |
Shares Outstanding | 38.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.83 |
Book Value | $2.96 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -967.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
